by Raynovich Rod | Jul 2, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biotechnology Sector (IBB 178) Up Over 30% YTD Many Rayno Focus Stocks Outperformed the Market NASDAQ 3431 , S&P 1615 Biopharmaceutical-Top 5 Stocks- % Up YTD Albany Molecular (AMRI) 140.7 Alkermes (ALKS) 59.3 Astex (ASTX) up 49.5 Biogen Idec (BIIB) up 48.9...
by Raynovich Rod | Jul 1, 2013 | Biopharmaceuticals
Biotech Sector All Green Triggered By ONXX Bid A lagging biotech sector perked up today on the $10B bid for ONXX by Amgen(AMGN). Most Rayno Life Science stocks were up except Amgen which was down 0.19%. This is a tradable rally but one not likely to drive the sector...
by Raynovich Rod | Jun 27, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Bond Market Stabilizes A strong bond auction today for the 7 Year Treasury at an interest rate of 1.94% helped support the three day rally easing investor concerns about rising interest rates and liquidation of bonds. European and Japanese stocks were also up. Bond...
by Raynovich Rod | Jun 25, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Global Economic Picture Not Good-Healthcare A Laggard on Rally Day Strong housing and durable goods data supported the rally today taking the S&P up 0.95% and NASDAQ up 0.82%. Comments from the China’s Central Bank helped a recovery from a free fall in the...
by Raynovich Rod | Jun 20, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Rayno Diagnostics and Tools Portfolio Prices as of 5/29/13 Top 2013 Winners: ABAX, ALR, CSII, GHDX, ILMN, TMO, VRML Sector high was in mid-May Less volatile than biopharma but more dependent on earnings Five companies on focus list were acquired over 3 years...
by Raynovich Rod | Jun 14, 2013 | BIOgraph, Biopharmaceuticals
Biotech Sell-Off Continues Nothing dramatic but the overall weakness in biopharmaceutical stocks is continuing today despite a strong performance by NASDAQ up 1.2% at 3464. With biotech having one of it best years of all time, profit taking is expected. The most...
by Raynovich Rod | Jun 11, 2013 | BIOgraph, Biopharmaceuticals, Clinical Diagnostics and Tools
Life Science Stocks Holding Up Amidst Volatility-Stay Cautious Biotech stocks are mixed today as volatility from currency moves and violence in Turkey and the Middle East gives pause to investors. Bonds have corrected almost 5% prompting an exit from bond funds as the...
by Raynovich Rod | Jun 7, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools
Risk On With Jobs Data in Sweet Spot Life Science Stocks Rally 2+ % Stocks rose over 1% after analysts felt jobs report was “not too hot nor not too cold” extending sentiment for an accommodative FED. The rally is holding before the close as investors...
by Raynovich Rod | Jun 5, 2013 | BIOgraph, Biopharmaceuticals
Market Correction Is Here-IBB at 170 off 2%+ The biotech sector sell-off (IBB at $170) continues today despite an effort to rally in the opening (IBB at $178). The biotech sector now tracks the overall market and is no longer immune to macro issues and economic...
by Raynovich Rod | Jun 4, 2013 | BIOgraph, Biopharmaceuticals
Apparently ASCO Is “Sell On the News” Trigger Another lackluster trading day with profit taking; the IBB is down 2.3% and trading near its May bottom with a pronounced topping pattern.Moreover many funds and indices now own biotech stocks so without the...
